Journal article
Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration
JJ Arnold, A Campain, D Barthelmes, JM Simpson, RH Guymer, AP Hunyor, IL McAllister, RW Essex, N Morlet, MC Gillies
Ophthalmology | Published : 2015
Abstract
Purpose To report 24-month outcomes of anti-vascular endothelial growth factor (VEGF) therapy for treatment-naïve eyes with neovascular age-related macular degeneration (nAMD) using a treat and extend treatment regimen in routine clinical practice. Design Database observational study. Participants We included treatment-naïve eyes receiving predominantly ranibizumab for nAMD in routine clinical practice treated using a treat and extend regimen that were tracked in the Fight Retinal Blindness observational registry. Methods A cohort of eyes treated by practitioners using exclusively a treat and extend regimen was extracted from the Fight Retinal Blindness observational registry. Main Outcome M..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
Supported by a grant from the Royal Australian NZ College of Ophthalmologists Eye Foundation (2007-2009) and a grant from the National Health and Medical Research Council (grant no. 632663), Australia (NHRMC 2010-2012). The authors state they have no conflicts of interest to declare. Mark Gillies is a Sydney Medical Foundation Fellow and is supported by an NHMRC practitioner fellowship.